EXACT Sciences Corporation Stock News

Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ: NVDA ). The sector is also getting a lift from the U.S. Fe

The seven stable stocks discussed below each have the potential to double by 2025 based on analyst target prices. Each of the seven stocks is also relatively stable based on the fact that none have a

Underdogs stocks carry almost universal appeal. It's one thing to go with the rest of the crowd.

The STOCK Act of 2012 was supposed to halt insider trading by members of Congress, but let's be honest. The STOCK Act can't really stop Congresspeople from trading on insider knowledge; they're in a p

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow

Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.

Exact Sciences Corporation (EXAS) Q4 2023 Earnings Call Transcript

Exact Sciences (EXAS) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.72 per share a year ago.

Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2

I'm bullish on the long-term trajectory of personalized medicine stocks. These companies specialize in tailoring a holistic approach to healthcare, with medical treatments tailored to the individual c

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.

Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives.